Literature DB >> 7505026

Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression.

A Miller1, A al-Sabbagh, L M Santos, M P Das, H L Weiner.   

Abstract

We have been studying the suppression of experimental autoimmune encephalomyelitis in the Lewis rat after oral administration of myelin basic protein (MBP). Suppression is mediated by CD8+ T cells that adoptively transfer protection and suppress immune responses in vitro. This suppression is mediated by secretion of TGF-beta following triggering by the fed antigen. In the present study, we tested the ability of overlapping 20 amino acid peptides from MBP to trigger suppression mediated by spleen cells from Lewis rats orally tolerized to MBP. Using a transwell system, we found that spleen cells from MBP orally tolerized animals stimulated by residues 21-40, 51-70 and 101-120 of MBP suppress proliferative responses of an ovalbumin specific cell line. This suppression correlated with secretion of TGF-beta by cells stimulated with the peptide. In addition, T cells from animals fed the tolerogenic peptide 21-40 alone secreted TGF-beta whereas no TGF-beta release or in vitro suppression was observed in animals fed the MBP encephalitogenic determinant 71-90. The 71-90 peptide triggered proliferation of MBP primed cells from animals immunized with MBP/CFA whereas the suppressor epitopes identified above did not. Furthermore, oral administration of peptide 21-40 suppressed disease induced by peptide 71-90. DTH responses to 71-90 were not affected by oral administration of peptide 21-40 whereas DTH responses to whole MBP were suppressed. These results demonstrate that distinct suppressor determinants exist on MBP which are separate from encephalitogenic determinants, and that epitope-driven bystander suppression plays an important role in down-regulation of tissue specific autoimmune processes following oral tolerization. These findings have important implications for the design of tissue specific targeted immunotherapy by oral tolerization in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505026

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  An investigation of the ability of orally primed and tolerised T cells to help B cells upon mucosal challenge.

Authors:  Natalie Kobets; Kim Kennedy; Deborah O'Donnell; Paul Garside
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

Review 2.  New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity.

Authors:  Hirofumi Ochi; Michal Abraham; Hiroki Ishikawa; Dan Frenkel; Kaiyong Yang; Alexandre Basso; Henry Wu; Mei-Ling Chen; Roopali Gandhi; Ariel Miller; Ruth Maron; Howard L Weiner
Journal:  J Neurol Sci       Date:  2008-09-18       Impact factor: 3.181

Review 3.  Prospects for induction of tolerance in renal transplantation.

Authors:  A M Krensky; C Clayberger
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

Review 4.  Oral tolerance and the treatment of rheumatoid arthritis.

Authors:  H L Weiner; Y Komagata
Journal:  Springer Semin Immunopathol       Date:  1998

Review 5.  Oral tolerance.

Authors:  W Strober; B Kelsall; T Marth
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

Review 6.  Regulation of mucosal immune responses: distinct antigens and antigen presenting cells.

Authors:  L Mayer
Journal:  J Clin Immunol       Date:  1997-09       Impact factor: 8.317

7.  Lymphocytes from orally tolerized mice display enhanced susceptibility to death by apoptosis when cultured in the absence of antigen in vitro.

Authors:  P Garside; M Steel; E A Worthey; P J Kewin; S E Howie; D J Harrison; D Bishop; A M Mowat
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

8.  A subset of gamma delta T-cell receptor-positive cells produce T-helper type-2 cytokines and regulate mouse skin graft rejection following portal venous pretransplant preimmunization.

Authors:  R M Gorczynski; Z Chen; Y Hoang; B Rossi-Bergman
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

9.  Calcium intervention ameliorates experimental model of multiple sclerosis.

Authors:  Dariush Haghmorad; Mohammad B Mahmoudi; Mahmoud Mahmoudi; Shahrzad Z T Rab; Maryam Rastin; Hamid Shegarfi; Gholamreza Azizi; Abbas Mirshafiey
Journal:  Oman Med J       Date:  2014-05

10.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.